Alternative use of bisphosphonate therapy for rheumatic disease

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 3045-3052

  Le Goff, B ^a   Berthelot, J M ^a,b   Maugars, Y ^b   Romas, E ^c  

^a Universite de Nantes   (France)

^b HÔTEL DIEU   (France)

^c St Vincents Institute   (Australia)

Author keywords

Algodystrophy; Animals model; Aseptic osteitis; Bisphosphonates; Charcot's neuro osteoarthropathy; Complex regional pain type i; Fibrous dysplasia; Methotrexate; Osteoclast; Osteonecrosis; Rheumatoid arthritis; SAPHO; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONODRONATE; INTERLEUKIN 6; PAMIDRONIC ACID; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ALGODYSTROPHY; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; BONE DENSITY; BONE NECROSIS; BONE REMODELING; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FIBROUS DYSPLASIA; FUNCTIONAL STATUS; HUMAN; NEUROPATHIC JOINT DISEASE; OSTEOLYSIS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SINGLE DRUG DOSE; SUPPLEMENTATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHROPATHY, NEUROGENIC; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; REFLEX SYMPATHETIC DYSTROPHY; RHEUMATIC DISEASES;

EID: 78649897872     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563626     Document Type: Review

References (84)

1. Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 2005; 19: 1065-79.
2. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 2008; 16: 1105-15.
3. Pennanen N, Lapinijoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1, IL-6 and TNF- secretion from RAW264 cells in vitro. Pharm Res 1995; 12: 916-22.
4. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate: mechanism of action. Mini Rev Med Chem 2004; 4: 711-9.
5. Bonabello A, Galmozzi MR, Canaparo R, Serpe L, Zara GP. Longterm analgesic effect of clodronate in rodents. Bone 2003; 33: 567-74.
6. Bishop NJ, Ninkovic M, Alexander GJ, et al. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively. Clin Sci (Lond) 1999; 97: 157-63.
7. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051-8.
8. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumato 1998; 27: 38-41.
9. Pennanen N, Lapinijoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1, IL-6 and TNF- secretion from RAW264 cells in vitro. Pharmacol Res 1995; 12: 916-22.
10. Richards PJ, Amos N, Williams AS, Williams BD. Proinflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology (Oxford) 1999; 38: 984-91.
11. Hsu ES. Practical management of complex regional pain syndrome. Am J Ther 2009; 16: 147-54.
12. Basle MF, Rebel A, Renier JC. Bone tissue in reflex sympathetic dystrophy syndrome--Sudeck's atrophy: structural and ultrastructural studies. Metab Bone Dis Relat Res 1983; 4: 305-11.
13. Maillefert JF, Chatard C, Owen S, Peere T, Tavernier C, Tebib J. Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis 1995; 54: 687.
14. Cortet B, Flipo RM, Coquerelle P, Duquesnoy B, Delcambre B. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol 1997; 16: 51-6.
15. Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997; 56: 201-4.
16. Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1477-83.
17. Robinson JN, Sandom J, Chapman PT. Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004; 5: 276-80.
18. Manicourt DH, Brasseur JP, Boutsen Y, Depreseux G, Devogelaer JP. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004; 50: 3690-7.
19. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-96.
20. van der Ven A, Chapman CB, Bowker JH. Charcot neuroarthropathy of the foot and ankle. J Am Acad Orthop Surg 2009; 17: 562-71.
21. Gough A, Abraha H, Li F, et al. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 1997; 14: 527-31.
22. Jostel A, Jude EB. Medical treatment of Charcot neuroosteoarthropathy. Clin Podiatr Med Surg 2008; 25: 63-9.
23. Guis S, Pellissier JF, Arniaud D, et al. Healing of Charcot's joint by pamidronate infusion. J Rheumatol 1999; 26: 1843-5.
24. Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 1994; 11: 28-31.
25. Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001; 44: 2032-7.
26. Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM. Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surg 2004; 43: 285-9.
27. Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005; 28: 1214-5.
28. Chamot AM, Benhamou CL, Kahn MF, Beraneck I, Kaplan G, Prost A. Le syndrome acne pustulose hyperostose osteite (SAPHO): resultats d'une enquete nationale. 85 observations. Rev Rhum Mal Osteoartic 1987; 54: 187-96.
29. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999; 29: 159-71.
30. Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology (Oxford) 2002; 41: 231-3.
31. Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A. Pamidronate treatment in SAPHO syndrome. Joint Bone Spine 2002; 69: 392-6.
32. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 2004; 43: 658-61.
33. Solau-Gervais E, Soubrier M, Gerot I, et al. The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 2006; 45: 339-42.
34. Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 2004; 50: 2970-3.
35. Ichikawa J, Sato E, Haro H, Ando T, Maekawa S, Hamada Y. Successful treatment of SAPHO syndrome with an oral bisphosphonate. Rheumatol Int 2009; 29: 713-5.
36. Ben M'Barek R, Grosjean C, Quintin E, et al. Bisphosphonates et syndrome SAPHO: à propos de 68 observations. Rev Rhum 2009; 76: 1025-6 (Abstract).
37. Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune- Albright syndrome. Best Pract Res Clin Rheumatol 2008; 22: 55-69.
38. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-95.
39. Shenker A, Weinstein LS, Sweet DE, Spiegel AM. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994; 79: 750-5.
40. Marie PJ, de Pollak C, Chanson P, Lomri A. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997; 150: 1059-69.
41. Spiegel AM. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab 1996; 81: 2434-42.
42. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953-4.
43. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35: 235-42.
44. Chao K, Katznelson L. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull. J Neurosurg 2008; 109: 889-92.
45. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006; 21: 114-9.
46. Lala R, Matarazzo P, Andreo M, et al. Study Group for Gs alpha Protein Related Diseases of the Italian Society for Pediatric Endocrinology and Diabetes. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006; 19: 583-93.
47. Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15: 929-37.
48. Isaia GC, Lala R, Defilippi C, et al. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tissue Int 2002; 71: 121-8.
49. Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum 1993; 23: 47-69.
50. Sweet DE, Madwell JE. Osteonecrosis: pathogenesis. In: Resnick D, Ed. Diagnosis of bone and joint disorders. Philadelphia: WB Saunders Co 1995: p. 3447, 3457-58, 3460, 3463, 3465.
51. Sen RK. Management of avascular necrosis of femoral head at precollapse stage. Indian J Orthop 2009; 43: 6-16.
52. Mont MA, Hungerford DS. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995; 77: 459-74.
53. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41: 346-7.
54. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 2005; 44: 352-9.
55. Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br 2009; 91: 1013-8.
56. Lackner H, Benesch M, Moser A, et al. Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study. J Pediatr Hematol Oncol 2005; 27: 259-63.
57. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am 2007; 89: 1727-34.
58. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005; 87: 2155-9.
59. Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004; 104: 1253-7.
60. Harinck HI, Bijvoet OL, van der Meer JW, et al. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet 1984; 2: 513.
61. Ciana G, Cuttini M, Bembi B: Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 1997; 337: 712.
62. Samuel R, Katz K, Papapoulos SE, et al. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 1994; 94: 385.
63. Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 330-6.
64. Tengstrand B, Hafström I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 2002; 29: 2299-305.
65. Reid DM, Devogelaer JP, Saag K, et al. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63.
66. Mawatari T, Miura H, Hamai S, et al. Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 2008; 58: 3340-9
67. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996; 39: 396-402.
68. Itoh F, Aoyagi S, Kusama H, Kojima M, Kogo H. Effects of clodronate and alendronate on local and systemic changes in bone metabolism in rats with adjuvant arthritis. Inflammation 2004; 28: 15-21.
69. Harada H, Nakayama T, Nanaka T, Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvantinduced arthritis. Inflamm Res 2004; 53: 45-52.
70. Le Goff B, Soltner E, Charrier C, et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 2009; 11: R185.
71. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004; 50: 2338-46.
72. Herrak P, Görtz B, Hayer S, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004; 50: 2327-37.
73. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003; 30: 474-9.
74. Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994; 23: 211-4.
75. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 396-9.
76. Valleala H, Laasonen L, Koivula MK, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30: 468-73.
77. Van Offel JF, Schuerwegh AJ, Bridts CH, et al. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 2001; 19: 13-20.
78. Jarrett SJ, Conaghan PG, Sloan VS, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2006; 54: 1410-4.
79. Cohen SB, Dore RK, Lane NE, et al. Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo- controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-309.
80. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pami-dronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994; 21: 2016-20.
81. Soejima M, Kawaguchi Y, Hara M, Saito S, Kamatani N, Yamanaka H. Therapeutic effects of alendronate on bone erosion and atrophy in a patient with rheumatoid arthritis and hepatitis C virus infection. J Rheumatol 2008; 35: 2284-6.
82. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.
83. Ruderman EM. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr Pharm Des 2005; 11(5): 671-84.
84. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-44.